These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 16440364)
1. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Sokal EM; Kelly DA; Mizerski J; Badia IB; Areias JA; Schwarz KB; Vegnente A; Little NR; Gardener SD; Jonas MM Hepatology; 2006 Feb; 43(2):225-32. PubMed ID: 16440364 [TBL] [Abstract][Full Text] [Related]
2. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. Jonas MM; Little NR; Gardner SD; J Viral Hepat; 2008 Jan; 15(1):20-7. PubMed ID: 18088241 [TBL] [Abstract][Full Text] [Related]
3. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN; Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543 [TBL] [Abstract][Full Text] [Related]
4. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663 [TBL] [Abstract][Full Text] [Related]
5. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. Yao GB; Zhu M; Cui ZY; Wang BE; Yao JL; Zeng MD J Dig Dis; 2009 May; 10(2):131-7. PubMed ID: 19426396 [TBL] [Abstract][Full Text] [Related]
6. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B. Yao G; Cui Z; Wang B; Yao J; Zeng M Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Tassopoulos NC; Volpes R; Pastore G; Heathcote J; Buti M; Goldin RD; Hawley S; Barber J; Condreay L; Gray DF Hepatology; 1999 Mar; 29(3):889-96. PubMed ID: 10051494 [TBL] [Abstract][Full Text] [Related]
8. A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B. Yao GB; Cui ZY; Wang BE; Yao JL; Zeng MD Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):188-93. PubMed ID: 15138107 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536 [TBL] [Abstract][Full Text] [Related]
11. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966 [TBL] [Abstract][Full Text] [Related]
12. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Hartman C; Berkowitz D; Shouval D; Eshach-Adiv O; Hino B; Rimon N; Satinger I; Kra-Oz T; Daudi N; Shamir R Pediatr Infect Dis J; 2003 Mar; 22(3):224-9. PubMed ID: 12634582 [TBL] [Abstract][Full Text] [Related]
13. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels. Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116 [TBL] [Abstract][Full Text] [Related]
14. Long-term therapy of chronic hepatitis B with lamivudine. Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630 [TBL] [Abstract][Full Text] [Related]
15. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Chan HL; Wang H; Niu J; Chim AM; Sung JJ Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024 [TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*. Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556 [TBL] [Abstract][Full Text] [Related]
17. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171 [TBL] [Abstract][Full Text] [Related]
18. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients]. Zhu M; Xu B; Yao GB Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B]. Kim JM; Choe BH; Chu MA; Cho SM Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769 [TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Yao G; Wang B; Cui Z; Yao J; Zeng M Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]